• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    1/10/24 4:31:09 PM ET
    $ATNF
    $CARM
    $COGT
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email

    Gainers

    • Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 6.7% to $0.26 during Wednesday's after-market session. The company's market cap stands at $4.8 million.
    • Semler Scientific (NASDAQ:SMLR) shares rose 5.99% to $52.87. The market value of their outstanding shares is at $363.3 million.
    • China Pharma Holding (AMEX:CPHI) stock rose 5.82% to $0.1. The company's market cap stands at $3.2 million.
    • CARISMA Therapeutics (NASDAQ:CARM) stock rose 5.07% to $2.9. The market value of their outstanding shares is at $117.0 million.
    • Purple Biotech (NASDAQ:PPBT) stock increased by 4.99% to $0.7. The company's market cap stands at $17.2 million.
    • Sangamo Therapeutics (NASDAQ:SGMO) shares increased by 4.99% to $0.58. The market value of their outstanding shares is at $102.4 million.

    Losers

    • 180 Life Sciences (NASDAQ:ATNF) shares fell 18.2% to $0.25 during Wednesday's after-market session. The company's market cap stands at $2.4 million.
    • Cartesian Therapeutics (NASDAQ:RNAC) shares decreased by 9.74% to $0.74. The market value of their outstanding shares is at $119.1 million.
    • Alpha Tau Medical (NASDAQ:DRTS) stock fell 7.28% to $3.06. The company's market cap stands at $212.5 million.
    • Cogent Biosciences (NASDAQ:COGT) stock fell 6.2% to $5.0. The company's market cap stands at $430.6 million.
    • Exicure (NASDAQ:XCUR) shares declined by 5.47% to $0.74. The market value of their outstanding shares is at $6.4 million.
    • NewAmsterdam Pharma (NASDAQ:NAMS) shares fell 5.4% to $16.3. The market value of their outstanding shares is at $1.3 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATNF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF
    $CARM
    $COGT
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    NewAmsterdam Pharma Company N.V.
    $NAMS
    3/18/2026$57.00Buy
    Truist
    Cogent Biosciences Inc.
    $COGT
    3/16/2026Buy
    Jefferies
    Cartesian Therapeutics Inc.
    $RNAC
    3/9/2026$16.00Neutral → Overweight
    Cantor Fitzgerald
    Alpha Tau Medical Ltd.
    $DRTS
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    Cogent Biosciences Inc.
    $COGT
    11/10/2025$40.00Hold → Buy
    Stifel
    Cogent Biosciences Inc.
    $COGT
    11/10/2025$38.00Neutral → Outperform
    Wedbush
    Sangamo Therapeutics Inc.
    $SGMO
    11/7/2025$1.00Overweight → Equal Weight
    Barclays
    NewAmsterdam Pharma Company N.V.
    $NAMS
    10/20/2025$52.00Buy
    H.C. Wainwright
    More analyst ratings

    $ATNF
    $CARM
    $COGT
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barabe Timothy C bought $205,797 worth of shares (30,000 units at $6.86), increasing direct ownership by 123% to 54,366 units (SEC Form 4)

    4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

    12/8/25 4:07:12 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $15,639 worth of Ordinary Shares (660 units at $23.70) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    9/17/25 5:22:34 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $31,487 worth of Ordinary Shares (1,260 units at $24.99) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    9/10/25 5:19:10 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $CARM
    $COGT
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cartesian Therapeutics Announces New Employment Inducement Grants

    FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On April 1, 2026, the Company issued to these employees options to purchase an aggregate of 52,450 shares of the Company's common stock with an exercise price of $6.39, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Co

    4/2/26 7:05:00 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

    Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination demonstrated 16.5 month mPFS and 46% ORR in imatinib-resistant GIST patients, dramatically improving upon the current standard of care WALTHAM, Mass. and BOULDER, Colo., April 01, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastin

    4/1/26 8:00:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

    JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, the world's premier international gastroenterology conference. This marks the first time that clinical results of Alpha DaRT in pancreatic cancer patients have been selected for presentation at a major gastroenterology conference. The abstract, entitled "Updated Results of Feasibility, Safety, and Tumor Control

    3/31/26 9:15:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $ATNF
    $CARM
    $COGT
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Zilberberg Suzana

    3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)

    4/7/26 2:56:13 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Agmon Ido

    3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)

    4/6/26 4:48:48 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hoge Elizabeth

    4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

    4/6/26 4:28:25 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $CARM
    $COGT
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on NewAmsterdam Pharma with a new price target

    Truist initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $57.00

    3/18/26 3:54:27 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Cogent Biosciences

    Jefferies resumed coverage of Cogent Biosciences with a rating of Buy

    3/16/26 9:35:47 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartesian Therapeutics upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Cartesian Therapeutics from Neutral to Overweight and set a new price target of $16.00

    3/9/26 10:58:35 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $CARM
    $COGT
    $CPHI
    SEC Filings

    View All

    Exicure Inc. filed SEC Form 8-K: Leadership Update

    8-K - EXICURE, INC. (0001698530) (Filer)

    4/10/26 4:15:47 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - EXICURE, INC. (0001698530) (Filer)

    4/2/26 4:15:02 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by China Pharma Holdings Inc.

    10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

    4/1/26 4:15:23 PM ET
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $CARM
    $COGT
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    Purple Biotech Announces CEO Transition

    Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing next-generation cancer therapies, today announced that Gil Efron, Chief Executive Officer, will step down from his role as CEO effective August 2026. Mr. Efron will remain actively involved with the Company, transitioning to lead corporate development and continuing as a member of the Board of Directors. In this new capacity, he will focus on identifying strategic initiatives, partnerships, and support the Company's financing activities as needed

    3/13/26 8:04:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Strive Announces the Completion of Semler Scientific Acquisition

    DALLAS, TX, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (NASDAQ:ASST) ("Strive") today announced the successful completion of the previously announced acquisition of Semler Scientific. Strive now holds approximately 12,797.9 bitcoin, becoming the #11 largest public corporate holder of bitcoin globally. Strive also announces the appointment of Avik Roy as Chief Strategy Officer of Strive. Mr. Roy's initial focus will be on Strive's intentions to monetize the operating business from the Semler Scientific subsidiary by expanding its mandate in early disease detection products.  Mr. Roy began his career in science at MIT and trained as a physician at Yale Medical School before joining Ba

    1/16/26 8:40:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

    Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune dise

    1/9/26 8:04:14 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $CARM
    $COGT
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $CARM
    $COGT
    $CPHI
    Financials

    Live finance-specific insights

    View All

    Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

    Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in study, which U.S. Food and Drug Administration (FDA) reiterated in October may serve as primary basis of approval under Accelerated Approval pathway Rolling submission of Biologics License Agreement (BLA) to FDA seeking ST-920 approval is in progress Transitioned to a clinical-stage neurology company with six clinical sites activated in Phase 1/2 STAND study in chronic neuropathic pain Announced in April, third neurology capsid license agreement, this time with Eli

    3/30/26 4:01:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

    RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2025 financial results after the market closes on Monday, March 30, 2026. The company will hold a conference call at 4:30 p.m. Eastern on Monday, March 30, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participa

    3/19/26 4:03:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care